CARY, N.C. and BASEL, Switzerland, Sept. 13, 2021 /PRNewswire/ — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, presented an e-poster at the European Respiratory Society annual congress highlighting the protocol and design of the ongoing double-blind, placebo-controlled […]
Tag: PAH
Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards
Seven U.S. researchers working to advance pulmonary hypertension (PH) science and patient care awarded a combined one million dollars in grants Application for the 2021 PHAB Awards is now live for eligible researchers to submit their proposals WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer […]
CARMAT Announces the First Human Implant of its Aeson® Artificial Heart in Germany
The implant was performed at Hannover Medical School PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart […]
Pulnovo Medical: a Pulmonary Arterial Hypertension medical device company completed the world’s first pulmonary hypertension treatment device RCT study after achieving FDA Breakthrough designation.
NANJING, China, June 28, 2021 /PRNewswire/ — Recently, Pulnovo Medical’s PADN-CFDA clinical trial, the world’s first pulmonary hypertension treatment device RCT study, has completed all patients enrollment, and will continue to assist each enrollment center to complete the follow-up of enrolled patients, data […]
Aerami Therapeutics Initiates Dosing in Phase 1 Trial of AER-901, Its Proprietary Inhaled Imatinib for the Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifying Dosing of patients in Phase 1 trial is currently ongoing with results expected later this year Plans to enter Phase 2/3 […]
Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference
– Treatment with sotatercept in the ongoing SPECTRA Phase 2 trial was associated with improvements in resting and exercise hemodynamics at week 24 – – Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH and […]
Altavant Sciences Provides Update on Clinical Plan for PAH Candidate, Rodatristat Ethyl, at Upcoming American Thoracic Society Annual Meeting
CARY, N.C. and BASEL, Switzerland, May 10, 2021 /PRNewswire/ — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, will be providing an update on the clinical development of rodatristat ethyl, the company’s lead candidate for the treatment of pulmonary […]
Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension
Cary, N.C. and Basel, Switzerland, May 06, 2021 (GLOBE NEWSWIRE) — Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company has initiated its ELEVATE 2 Study, a Phase 2b clinical […]
New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients
Data from the SPHERE Registry published in the Journal of Heart and Lung Transplantation SOUTH SAN FRANCISCO, Calif., April 6, 2021 /PRNewswire/ — Findings from an analysis of the first 500 patients enrolled in the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) found […]
Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine
The prospective, randomized, controlled, open-label study, which included outcomes from 226 patients with pulmonary arterial hypertension (PAH) (WHO Group 1), met its primary endpoint WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE (Riociguat […]